Linked Life Data

10100554

Source:http://linkedlifedata.com/resource/pubmed/id/10100554

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1999-6-22
pubmed:abstractText
The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m2 with docetaxel 100 mg/m2, in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m2 of CY. The median yield of CD34+ cells from all patients was 11.06x10(6)/kg (range, 0.03-84.77) from a median of two aphereses (range, 1-7); 6.52x10(6) CD34+ cells/kg/apheresis (range, 0.01-52.07). Target CD34+ cell doses > or =2.5 and > or =5.0x10(6)/kg were achieved in 89% and 79%, respectively. There were no statistically significant differences in CD34+ cell yields or target CD34+ cell doses achieved following 3 or 4 g/m2 of CY. Patients with only one prior chemotherapy regimen yielded a median of 12.82x10(6) CD34+ cells/kg/apheresis compared to 5.85 for those receiving > or =2 regimens (P = 0.03). It was concluded that the combination of docetaxel, 100 mg/m2, CY 3 g/m2 without mesna could be administered with acceptable toxicity with collection of adequate quantities of PBSC from the majority of patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
421-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:10100554-Adult, pubmed-meshheading:10100554-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10100554-Blood Cell Count, pubmed-meshheading:10100554-Breast Neoplasms, pubmed-meshheading:10100554-Combined Modality Therapy, pubmed-meshheading:10100554-Cyclophosphamide, pubmed-meshheading:10100554-Female, pubmed-meshheading:10100554-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:10100554-Hematopoietic Stem Cell Mobilization, pubmed-meshheading:10100554-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:10100554-Hematopoietic Stem Cells, pubmed-meshheading:10100554-Humans, pubmed-meshheading:10100554-Middle Aged, pubmed-meshheading:10100554-Neoplasm Metastasis, pubmed-meshheading:10100554-Paclitaxel, pubmed-meshheading:10100554-Recombinant Proteins, pubmed-meshheading:10100554-Taxoids
pubmed:year
1999
pubmed:articleTitle
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
pubmed:affiliation
Clinical Research Division of Response Oncology, Inc, Memphis, TN, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial